Kings Research today announced the release of its latest market intelligence study, “Global Prostate Cancer Market: Size, Share, Trends & Forecast 2024–2031.” The report provides a comprehensive analysis of market drivers, emerging therapies, regional dynamics, and competitive developments shaping the prostate cancer treatment landscape.
According to Kings Research, the global prostate cancer market was valued at USD 12.72 billion in 2024, and is projected to hit USD 21.45 billion by 2031, exhibiting a CAGR of 7.74% during 2024–2031. Market growth is supported by an aging population, high disease prevalence, and advances in medical technology that improve diagnosis and treatment outcomes.
Prostate cancer originates in the prostate gland and remains one of the most common malignancies among men. Screening methods such as PSA (prostate-specific antigen) testing and digital rectal exams enable earlier detection, while treatment options range from active surveillance to surgery, hormone therapy, radiation, and targeted therapeutics. Continuous innovation in diagnostics and therapies is enhancing survival rates and quality of life for patients worldwide.
Kings Research identifies the following growth accelerators
- Rising Incidence and Aging Demographics
The American Cancer Society reports that about 313,780 new prostate cancer cases were diagnosed in the United States in 2025, with approximately 35,770 deaths (Source: www.cancer.org). Longer life expectancy and lifestyle factors continue to expand the global at-risk population.
- Regulatory Approvals & Advanced Therapies
-
- November 2023: XTANDI (enzalutamide) from Astellas and Pfizer became the first androgen receptor signaling inhibitor approved for nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
- August 2023: The U.S. FDA approved Akeega (niraparib + abiraterone acetate) with prednisone for BRCA-mutated castration-resistant prostate cancer. These approvals broaden treatment options and improve patient outcomes.
- Government Funding & Screening Initiatives
Expanded public health programs and cancer-screening campaigns in North America, Europe, and Asia-Pacific are increasing early detection rates and facilitating timely interventions.
- Precision Medicine & Genomic Profiling
Biomarker testing and genomic analysis enable more targeted treatment strategies, enhancing therapeutic efficacy and minimizing side effects.
For hospitals, payers, and pharmaceutical innovators, the prostate cancer market presents opportunities to
- Improve Patient Outcomes: New targeted and combination therapies extend survival and enhance quality of life.
- Expand Market Access: Broader screening and early diagnosis drive demand for diagnostic tools and pharmaceuticals.
- Differentiate Through Innovation: Precision medicine and next-generation therapeutics create competitive advantages.
Regional Outlook
- North America: Largest market with 45.09% share (USD 5.38 billion in 2023), supported by advanced healthcare infrastructure, high screening rates, and rapid adoption of novel treatments.
- Asia-Pacific: Expected to grow at a 9.68% CAGR through 2031 due to increasing incidence, rising healthcare expenditure, and supportive government cancer-care initiatives.
- Europe, Latin America, Middle East & Africa: Anticipated steady growth as awareness campaigns and improved access to diagnostics and therapies expand patient care.
Competitive Landscape
Prominent companies are strengthening their market positions through R&D investments, product launches, and strategic partnerships. Key players include Johnson & Johnson Services, Inc., Astellas Pharma Inc., Eli Lilly and Company, Sanofi, Ipsen Pharma, and Bayer AG.
The full Kings Research report provides detailed segmentation by drug class, end user, and region, along with competitive benchmarking and long-term forecasts. To request a sample or access the complete report, please visit https://www.kingsresearch.com/prostate-cancer-market-894.
About Kings Research
Kings Research is a global provider of syndicated research reports and consulting services, helping organizations navigate emerging markets, assess opportunities, and make informed business decisions.
All market data are sourced from Kings Research proprietary analysis, validated against credible public sources such as the American Cancer Society (www.cancer.org) and the U.S. Food and Drug Administration (www.fda.gov).